The strategic imperative of Integrated Evidence Generation Planning
Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations. As the complexity of therapies - and the expectation from regulators, payers, and patients continues to rise - the need to execute IEGP effectively becomes even more critical. The challenges of IEGP are significant: missed data, misaligned priorities, and delayed launches can cost companies millions, slow patient access, and erode trust.
In a new white paper from Lumanity, Integrated Evidence Generation Planning: A strategic imperative for biopharma innovation, best-practice considerations for IEGP are presented alongside real-world case studies. The real value of the “integrated” part of IEGP comes from engaging, understanding, and aligning cross-functional teams, resulting in both time and cost savings.
This white paper distils IEGP into four core steps:
- Define the evidence needed based on future aspirations
- Assess the potential impact of the evolving future landscape
- Review current evidence already available
- Identify new evidence to be generated
This process requires cross-team collaboration - bringing together experts in RWE, HEOR, PRO, Patient, Medical, Commercial, and other areas - to create solutions that save time and resources.
This Lumanity-sponsored white paper also explores broader considerations: regulatory evolution, payer scrutiny, digital disruption, competitive intelligence, scenario planning, data sources, patient populations, the clinical development cycle, global harmonisation strategies, and more.
Ultimately, there are many approaches and processes to harmonise IEGP activities, drive efficiencies, and measure success. While well-defined processes are strongly encouraged, as they help prevent major oversights and improve efficiency, there is risk in pursuing efficiency for its own sake - which this white paper elaborates on.
IEGP has the power to transform evidence from a cost centre to a strategic accelerator. By uniting all functions, leveraging technology, and planning with global and patient-centric perspective, organisations can save time, reduce costs, and deliver real-world impact.
After all, the devil - as they say - is in the details.
Find out more here
About Lumanity
Lumanity is a leading global strategic partner for biopharmaceutical companies. We engineer breakthrough value to tackle our clients’ toughest challenges and transform lives. By combining deep scientific, clinical, medical, regulatory, and commercial expertise with advanced technology and AI-driven tools, Lumanity guides complex decision-making and execution across the entire medicine value creation journey.
With 1,200 highly specialized experts working in more than 50 countries, and offices in North America, the UK, the EU, and Asia, we collaborate with nearly all of the top pharmaceutical companies and over 100 biotechs worldwide.
Our integrated approach brings together strategy, evidence, engagement, and technology - helping clients navigate market complexities with confidence, accelerate commercial success, and ultimately improve patient health outcomes.
